About: Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge
Creator	Zheng, Xueying Jin, Tengchuan Yang, Zhao, Weng, Jianping Cheng, Linzhao Ma, Huan Zeng, Weihong Zhou, Peigen Hu, Xiaowen
Source	MedRxiv
abstract	Monitoring the levels of SARS-CoV-2 specific antibodies such as IgG, M and A in COVID-19 patient is an alternative method for diagnosing SARS-CoV-2 infection and an simple way to monitor immune responses in convalescent patients and after vaccination. Here, we assessed the levels of SARS-CoV-2 RBD specific antibodies in twenty-seven COVID-19 convalescent patients over 28-99 days after hospital discharge. Almost all patient who had severe or moderate COVID-19 symptoms and a high-level of IgG during the hospitalization showed a significant reduction at revisit. The remaining patients who had a low-level IgG during hospitalization stayed low at revisit. As expected, IgM levels in almost all convalescent patients reduced significantly or stayed low at revisit. The RBD-specific IgA levels were also reduced significantly at revisit. We also attempted to estimate decline rates of virus-specific antibodies using a previously established exponential decay model of antibody kinetics after infection. The predicted days when convalescent patients' RBD-specific IgG reaches to an undetectable level are approximately 273 days after hospital discharge, while the predicted decay times are 150 days and 108 days for IgM and IgA, respectively. This investigation and report will aid current and future studies to develope SARS-CoV-2 vaccines that are potent and long-lasting.
has issue date	2020-08-21(xsd:dateTime)
bibo:doi	10.1101/2020.08.17.20175950
has license	medrxiv
sha1sum (hex)	c172569e827ac0a2c8c0a76510cadfd54fed4cdb
schema:url	https://doi.org/10.1101/2020.08.17.20175950
resource representing a document's title	Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge
resource representing a document's body	covid:c172569e827ac0a2c8c0a76510cadfd54fed4cdb#body_text
is schema:about of	named entity 'Monitoring' named entity 'alternative' named entity 'predicted' named entity 'antibody' named entity 'predicted' named entity 'symptoms' named entity 'IgA' named entity 'virus-specific' named entity 'convalescent' named entity 'kinetics' named entity 'stayed' named entity 'IgM' named entity 'IgA' named entity 'REACHES' named entity 'VIRUS' named entity 'WAY' named entity 'HERE' named entity 'FUTURE' named entity 'ESTIMATE' named entity 'LEVELS' named entity 'VACCINES' named entity 'REDUCTION' named entity 'IgM' named entity 'patients' named entity 'SARS-CoV-2' named entity 'simple' named entity 'IgG' named entity 'COVID-19' named entity 'levels' named entity 'potent' named entity 'days' named entity 'convalescent' named entity 'hospital' named entity 'specific' named entity 'vaccination' named entity 'IgA' named entity 'immune' named entity 'COVID-19' named entity 'virus' named entity 'antibodies' named entity 'IgA' named entity 'IgM' named entity 'hospital discharge' named entity 'infection' named entity 'exponential decay' named entity 'IgG' named entity 'vaccination' named entity 'COVID' named entity 'levels' named entity 'IgG' named entity 'preprint' named entity 'infection' named entity 'virus' named entity 'IgA' named entity 'IgG' named entity 'IgM' named entity 'RBD' named entity 'peer review' named entity 'coronavirus' named entity 'preprint' named entity 'IgA' named entity 'SARS-CoV-2' named entity 'exponential decay' named entity 'medRxiv' named entity 'IgA' named entity 'clinical trial' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'medRxiv' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'peer review' named entity 'medRxiv'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software